GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » ClouDr Group Ltd (HKSE:09955) » Definitions » Cash Flow from Financing

ClouDr Group (HKSE:09955) Cash Flow from Financing : HK$188 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is ClouDr Group Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, ClouDr Group paid HK$0 Mil more to buy back shares than it received from issuing new shares. It received HK$172 Mil from issuing more debt. It paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0 Mil from paying cash dividends to shareholders. It spent HK$27 Mil on other financial activities. In all, ClouDr Group earned HK$145 Mil on financial activities for the six months ended in Dec. 2023.


ClouDr Group Cash Flow from Financing Historical Data

The historical data trend for ClouDr Group's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClouDr Group Cash Flow from Financing Chart

ClouDr Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
905.32 1,088.71 1,243.29 562.32 187.93

ClouDr Group Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial 535.54 -78.87 637.45 50.77 137.16

ClouDr Group Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

ClouDr Group's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

ClouDr Group's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$188 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ClouDr Group  (HKSE:09955) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

ClouDr Group's issuance of stock for the six months ended in Dec. 2023 was HK$0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

ClouDr Group's repurchase of stock for the six months ended in Dec. 2023 was HK$0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

ClouDr Group's net issuance of debt for the six months ended in Dec. 2023 was HK$172 Mil. ClouDr Group received HK$172 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

ClouDr Group's net issuance of preferred for the six months ended in Dec. 2023 was HK$0 Mil. ClouDr Group paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

ClouDr Group's cash flow for dividends for the six months ended in Dec. 2023 was HK$0 Mil. ClouDr Group received HK$0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

ClouDr Group's other financing for the six months ended in Dec. 2023 was HK$-27 Mil. ClouDr Group spent HK$27 Mil on other financial activities.


ClouDr Group Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of ClouDr Group's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


ClouDr Group (HKSE:09955) Business Description

Traded in Other Exchanges
Address
No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. Its offerings include in-hospital solutions, pharmacy solutions, and individual chronic condition management solutions. The company's in-hospital solution consists of sales of medical devices, consumables and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies. It generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
Executives
Trident Trust Company (hk) Limited 2301 Trustee
Data Vantage Development Limited 2201 Interest of corporation controlled by you
Kuang Ming 2201 Interest of corporation controlled by you
Prime Forest Assets Limited 2101 Beneficial owner
Shang Hai Qi Ji Ke Ji He Huo Qi Ye You Xian He Huo
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si
Zhao Yin Guo Ji Jin Rong You Xian Gong Si
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si
Zhao Yin Guo Ji Jin Rong Kong Gu Shen Zhen You Xian Gong Si
Ho Chi Sing 2201 Interest of corporation controlled by you
China Merchants Bank Co., Ltd.
Zhou Quan 2201 Interest of corporation controlled by you
Idg China Venture Capital Fund Gp Iv Associates Ltd. 2201 Interest of corporation controlled by you
Haoyuan Health Limited 2101 Beneficial owner
Yass Jeffrey Steven

ClouDr Group (HKSE:09955) Headlines

No Headlines